ENXTPA:NANOBiotechs
Nanobiotix (ENXTPA:NANO) Secures $71 Million Royalty Financing Will Non-Dilutive Capital Reshape Its R&D Ambitions?
On October 31, Nanobiotix announced it had entered a royalty-based financing agreement with HealthCare Royalty to secure up to US$71 million in non-dilutive capital, supporting its operations and the advancement of nanotherapeutic platforms.
This agreement signals a reinforced financial position for Nanobiotix, potentially underpinning its ability to sustain research and development initiatives over the long term.
We’ll explore how this infusion of non-dilutive capital from the royalty-based...